ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2739 |
|
1599440-13-7 |
Deruxtecan | DS-8201a | exatecan derivative | DX 8951; 99+% |
C52H56FN9O13 | |
CL2727 |
|
1610413-97-2 |
PSMA-ligand-1 | Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid 98+% |
C34H54N4O10 | |
CL2725A |
|
169869-90-3 |
Exatecan Mesylate (DX8951f) 99+% |
C25H26FN3O7S | |
CL2724 |
|
1461704-01-7 |
Sulfo-PDBA-DM4 98+% |
C42H60ClN3O15S3 | |
CL2723 |
|
2344809-82-9 |
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br 97% |
C44H51BrN3O14P | |
CL2722 |
|
1626359-59-8 |
sulfo-SPDB-DM4 95+% |
C46H63ClN4O17S3 | |
CL2632A |
|
1795733-93-5 |
Seco-DUBA hydrochloride 95+% |
C29H23ClN4O4 · x HCl | |
CL2658 |
|
1595275-62-9 |
Tesirine(SG3249) 95+% |
C75H101N9O23 | |
CL2632 |
|
1227961-59-2 |
Seco-DUBA 95+% |
C29H23ClN4O4 | |
CL2266 |
|
59-05-2 |
Methotrexate 98+% |
C20H22N8O5 | |
CLA1342 |
|
1615697-16-9 |
Lifastuzumab (Anti-SLC34A2) 95+% |
— | |
CLA1247 |
|
1020264-78-1 |
Glembatumumab (Anti-GPNMB) 95+% |
— | |
CLA1065 |
|
400010-39-1 |
Cantuzumab 95+% |
— | |
CL1344 |
|
1345681-58-4 |
Vc-seco-DUBA (SYD985) 95+% |
C65H75ClN12O17 | |
CL1347 |
|
646502-53-6 |
VcMMAE; Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E; Mc-Val-Cit-PAB-MMAE 98+% |
C68H105N11O15 | |
HL1070 |
|
491-70-3 |
Luteolin 98+% |
C15H10O6 | |
CLA1052 |
|
1491917-83-9 |
Anti-Trop2 (sacituzumab govitecan biosimilar) mAb 98+% |
— | |
CLA1034 |
|
914088-09-8 |
Anti-CD30 (brentuximab vedotin biosimilar) mAb 95+% |
— | |
CLA1046 |
|
220578-59-6 |
Anti-CD33 (gemtuzumab ozogamicin biosimilar) mAb 95+% |
— | |